Switching from ranibizumab to aflibercept for eye conditions
Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration
This study is testing if switching patients with certain eye conditions from one medication to another can help improve their vision.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Medical University of Vienna Academic / other |
| Drugs / interventions | ranibizumab |
| Locations | 1 site (Vienna) |
| Trial ID | NCT02669953 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effects of switching patients with recurrent or persistent neovascular age-related macular degeneration (nAMD) and diabetic retinopathy from ranibizumab therapy to aflibercept. It includes 20 patients aged 50 and older who have been treated with ranibizumab for up to one year. Participants will undergo monthly examinations over a 12-month follow-up period to assess visual acuity and other ophthalmic parameters. The goal is to determine the efficacy of aflibercept in improving visual outcomes in these patients.
Who should consider this trial
Good fit: Ideal candidates are adults aged 50 and older who have been treated with ranibizumab for wet age-related macular degeneration.
Not a fit: Patients who have had recent eye surgery or uncontrolled glaucoma may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve visual function in patients with nAMD and diabetic retinopathy who have not responded adequately to previous treatment.
How similar studies have performed: Other studies have shown promising results with aflibercept in similar patient populations, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Adults ≥ 50 years * Patients who have been treated with ranibizumab due to wet age-related macular degeneration for up to one year * BCVA \>= 20/400 in the study eye using ETDRS * Willingness and ability to comply with regular visits * Signed informed consent Exclusion Criteria: * Any surgical treatment of the eye within 3 months prior to baseline in the study eye * History of uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma mediation) * Aphakia or absence of the posterior capsule (excluding YAG-capsulotomy) in the study eye * Retinal pigment epithelial tear involving the macula in the study eye
Where this trial is running
Vienna
- Medical University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Study coordinator: Reinhard Told, MD, PhD
- Email: reinhard.told@meduniwien.ac.at
- Phone: +43140400
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.